GlassScriptPhysician profile
Nathan Roger Perry
NPI 1073613295
$1,746.54
in general payments reported to CMS, 2019-2025
27 companies · $89.70 in 2025
The $89.70 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $170 · 2021: $449 · 2022: $267 · 2023: $50.51 · 2024: $149 · 2025: $89.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $296.01 | 2019-2022 | |
| Eisai INC. | $231.58 | 2020-2021 | |
| Daiichi Sankyo INC. | $205.39 | 2019-2021 | |
| Impel Pharmaceuticals INC. | $169.98 | 2022-2023 | Trudhesa |
| Abbvie INC. | $135.19 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $80.22 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $57.29 | 2019-2022 | |
| Impel Pharmaceuticals LLC | $49.89 | 2025 | Trudhesa |
| Astellas Pharma US INC | $48.20 | 2024-2025 | Veozah |
| Kaleo, INC. | $45.63 | 2019 | |
| Allergan, INC. | $42.49 | 2019-2020 | |
| Horizon Therapeutics Plc | $41.48 | 2021 | |
| Janssen Pharmaceuticals, INC | $36.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.52 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.10 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $30.96 | 2021-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $29.62 | 2021-2022 | |
| Exact Sciences Corporation | $24.98 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $20.88 | 2021 | |
| Dexcom, INC. | $19.81 | 2024 | Dexcom G6 Transmitter |
| Electromed, INC. | $18.26 | 2024 | Smartvest |
| Scilex Pharmaceuticals INC. | $17.84 | 2019 | |
| Corcept Therapeutics | $17.63 | 2024 | Korlym |
| Antares Pharma, INC. | $16.88 | 2019 | |
| Hikma Pharmaceuticals USA | $15.44 | 2019 | |
| Merck Sharp & Dohme LLC | $15.19 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.07 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.